AR073891A1 - Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades. - Google Patents

Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.

Info

Publication number
AR073891A1
AR073891A1 ARP090103993A ARP090103993A AR073891A1 AR 073891 A1 AR073891 A1 AR 073891A1 AR P090103993 A ARP090103993 A AR P090103993A AR P090103993 A ARP090103993 A AR P090103993A AR 073891 A1 AR073891 A1 AR 073891A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkynyl
alkenyl
haloalkyl
halogen
Prior art date
Application number
ARP090103993A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR073891A1 publication Critical patent/AR073891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto segun la formula 1 en donde A representa N, CH o CR1; cada R1 independientemente representa hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -C(O)-alquilo C1-6, -C(O)-alquenilo C2-6, -C(O)-alquinilo C2-6, -C(O)-O-alquilo C1-6, -C(O)-O-alquenilo C2-6, -C(O)-O-alquinilo C2-6 o fenilo, en donde dicho fenilo, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6, está opcionalmente sustituido con uno o más sustituyentes seleccionados de halogeno, hidroxilo, haloalquilo C1-6, nitro, alcoxi C1-6, y NR2R3; X representa hidrogeno, alquilo C1-6 o -CRaRb-X', en donde X' representa una porcion monocíclica saturada que tiene 5-6 átomos en el anillo uno de los cuales es N y en donde uno o dos átomos del anillo adicionales pueden ser un heteroátomo seleccionado de N, O y S, dicho anillo monocíclico puede estar sustituido con uno o más sustituyentes W, en donde W se selecciona de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6 o (=O); cada Ra y Rb representa individualmente hidrogeno, -CH3 o halogeno; Q representa -CH2- o -NH-; Y representa heteroarilo con 5-6 átomos en el anillo, en donde 1, 2 o 3 átomos en el anillo se seleccionan de O, N o S, o Y representa fenilo, en donde dicho heteroarilo o fenilo puede estar sustituido con uno o más sustituyentes seleccionados de halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 o alcoxi C1-6, en donde cada uno de R2 y R3 independientemente representa hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxialquilo C1-6, o haloalquilo C1-6; cada uno de R4-R8 y R9-R12 independientemente representa hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, NR2R3, hidroxi, ciano, nitro, alcoxi C1-6, haloalquilo C1-6 o hidroxialquilo C1-6; y sales farmacéuticamente aceptables de los mismos.
ARP090103993A 2008-10-20 2009-10-16 Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades. AR073891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200801458 2008-10-20

Publications (1)

Publication Number Publication Date
AR073891A1 true AR073891A1 (es) 2010-12-09

Family

ID=41479209

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103993A AR073891A1 (es) 2008-10-20 2009-10-16 Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.

Country Status (16)

Country Link
US (1) US8415373B2 (es)
EP (1) EP2350015A1 (es)
JP (1) JP2012505842A (es)
KR (1) KR20110070985A (es)
CN (1) CN102256948A (es)
AR (1) AR073891A1 (es)
AU (1) AU2009306819A1 (es)
BR (1) BRPI0919694A2 (es)
CA (1) CA2739946A1 (es)
CL (1) CL2011000865A1 (es)
CO (1) CO6361995A2 (es)
EA (1) EA201170585A1 (es)
IL (1) IL212107A0 (es)
MX (1) MX2011004034A (es)
TW (1) TW201016688A (es)
WO (1) WO2010045948A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148863A1 (en) * 2007-04-23 2010-02-03 Novartis Ag Phthalazine and isoquinoline derivatives with slp receptor modulating activities
EA201170074A1 (ru) 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
US8242134B2 (en) * 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
KR20130010283A (ko) 2011-07-18 2013-01-28 삼성전자주식회사 백색 발광 장치 및 이를 이용한 디스플레이 및 조명장치
US10653681B2 (en) * 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT940391E (pt) * 1994-05-27 2004-12-31 Glaxosmithkline Spa Derivados de quinolina como antagonistas do receptor de taquicinina nk3
GB0318727D0 (en) * 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
NZ544935A (en) 2003-08-15 2009-08-28 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
GB0425076D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
AU2006253054A1 (en) 2005-06-03 2006-12-07 Astrazeneca Ab Quinoline derivatives as NK3 anatgonists
CA2613001A1 (en) * 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as nk3 receptor modulators
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EA201170074A1 (ru) 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
MY164998A (en) 2008-09-15 2018-02-28 Sojournix Inc Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
EP2350015A1 (en) 2011-08-03
BRPI0919694A2 (pt) 2015-12-08
US20110288120A1 (en) 2011-11-24
TW201016688A (en) 2010-05-01
CN102256948A (zh) 2011-11-23
IL212107A0 (en) 2011-06-30
MX2011004034A (es) 2011-05-10
JP2012505842A (ja) 2012-03-08
AU2009306819A1 (en) 2010-04-29
CA2739946A1 (en) 2010-04-29
CO6361995A2 (es) 2012-01-20
CL2011000865A1 (es) 2011-09-23
US8415373B2 (en) 2013-04-09
WO2010045948A1 (en) 2010-04-29
KR20110070985A (ko) 2011-06-27
EA201170585A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
AR073891A1 (es) Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
BRPI0908120A8 (pt) Compostos que são inibidores de erk, composição faramacêutica e uso
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
AR073511A1 (es) Derivados de isoquinolinona como antagonistas de nk3
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR080032A1 (es) Compuestos de pirazol como antagonistas de crth2
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
AR072198A1 (es) Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
CL2007003481A1 (es) Compuestos derivados de 2-aminoquinolina, antagonistas de los receptores 5-ht5a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, esquizofrenia, d
PE20071224A1 (es) Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1)
AR080172A1 (es) (r) -4- ((4-((4-(tetrahidrofuran-3-iloxi) benzo (d) isoxazol-3-iloxi)metil)piperidin-1-il)metil) tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 y composiciones farmaceuticas que los comprenden
PE20090988A1 (es) Derivados de indol-2-ona como antagonistas del receptor de la grelina
AR055666A1 (es) Inhibidores inntr
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure